RepliCel Life Sciences Inc (OTCMKTS:REPCF) reported the granting of a major patent in the U.S. covering considering components of the firm’s unique, multi-needle dermal injection device. In the advancement of propriety cell treatment offerings targeting pattern baldness and sun-damaged or aging skin, the company’s dermatology team identified a need for advanced dermal injection know-how capable of getting new levels of control and precision to any substances put into the skin.
RepliCel Life Sciences reported that the patent issued by the USPTO relates to technologies intended to enable repeatable consistency and unparalleled control of product deposition and needle action. The patent also links to the element intended to numb the skin before injection with the planned effect of lowering, if not removing, the need for local anesthetic before aesthetic injection processes.
The first device being advanced under this patent is RCI-02 which is intended for injecting soft tissue fillers. As per the recent statistics report, the count of minimally invasive cosmetic processes performed countrywide in 2016 surpassed 11 million: more than 80% were hyaluronic acid filler injections and wrinkle treatments, totaling an expenditure of more than $3 billion. RCI-02 showcases the nearest-term commercial prospect for the firm, which it plans to keep market-ready and in the reach of a commercial partner and co-development licensee next year.
RepliCel Life Sciences reported that the device is being advanced for the injection of ‘RCS-01’ skin rejuvenation and ‘RCH-01’ hair restoration offerings. Future versions of the device will be enhanced for other injectable such as biologics, drugs, fat grafts, vaccines, etc.
Lee R. Buckler, the CEO of RepliCel, reported that they are confident company’s extensive patent estate for cell treatment and injection devices offer their offerings with long-term industry exclusivity. The granting of this patent is a vital addition to company’s formidable IP portfolio, which they consider will further create value for company’s investors.